Oral dihydroergotamine for therapy-resistant migraine attacks in children
Oral dihydroergotamine for therapy-resistant migraine attacks in children
复制标题
DOI：
10.1016/s0887-8994(96)00289-5
复制
发表时间：
1997-02-01
影响因子：
3.8
通讯作者：
Santavuori, PR
中科院分区：
文献类型：
--
作者：
Hamalainen, ML;Hoppu, K;Santavuori, PR
12名患有偏头痛症状的儿童对常规止痛药无反应，他们完成了一项双盲、安慰剂对照、交叉研究，研究中使用了两种剂量的口服双氢麦角胺（DHE）进行急性治疗。主要终点是在2小时时头痛减轻≥ 2级（5级量表）。DHE后，12名儿童中有7名达到主要终点，安慰剂后有2名达到主要终点[差异42%; 95%置信区间（CI）14%-70%]。7名受试者中有5名在DHE治疗后疼痛消失（3名20 μ g/kg; 2名40 μ g/kg）;安慰剂治疗后没有疼痛消失。5例中2例头痛复发。虽然头痛复发限制了口服DHE的疗效，但它可能对某些儿童偏头痛的急性治疗有用。(C)Elsevier Science Inc.出版。
Twelve children with migraine symptoms that did not respond to conventional analgesics completed a double-blind, placebo-controlled, cross-over study of two doses of oral dihydroergotamine (DHE) for acute treatment. The primary endpoint was reduction of headache by greater than or equal to 2 grades on a 5-grade scale at 2 hours. After DHE, 7 of the 12 children reached the primary endpoint, and 2 reached the primary endpoint after placebo [difference 42%; 95% confidence interval (CI) 14%-70%]. Five of the 7 were pain-free after DHE (3 with 20 mu g/kg; 2 with 40 mu g/kg); none was pain-free after placebo. Headache recurred in 2 of the 5. Although headache recurrence limits the efficacy of oral DHE, it may be useful in the acute treatment of migraine in selected children. (C) 1997 by Elsevier Science Inc.